The development of more effective cancer therapeutic strategies are still critically required. The maximization of the therapeutic effect in combination with avoiding the severe side effects on normal tissues when using chemotherapy drugs is still an urgent problem that requires improvements urgently. Here we provide implantable and controllable drug-release that utilises silk fibroin (SF) as a nanofibrous drug delivery system (DDS) for cancer treatment. A nanofibrous structure with controllable fibre diameter (<100 nm) was produced. The drug release rate of the SF DDS was controlled by applying a post-treatment process. In vitro anti-cancer (HCT116) results indicated that curcumin (CM)-SF nanofibrous matrix had a superior anti-cancer potential when the concentration was >5 µg/mL. The mechanism could be explained by the cell cycle being held in the S phase. The toxic effect on normal cells (NCM460) was minimized by using a treatment concentration range (5-20 µg/mL). Implantation of this DDS into the tumour site inhibited the growth of solid tumour; this offers an alternative approach for novel cancer therapy.
Introduction
Cancer is the leading cause of death in developed countries and the second most life-threatening disease in developing countries. Statistics from 2012 state there were 14.1 million new cases of cancer and 8.2 million of deaths in the world (Cancer Research UK). More than 50% of patients die of cancers due to the lack of efficient M A N U S C R I P T
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treatment. Chemotherapy is the widely and broadly used treatment, which always uses one or more chemotherapeutics to prolong life and or reduce symptoms [1, 2] .
However, current chemotherapeutic drugs have significant side effects on normal healthy cells and tissues if administrated by traditional routes; these are commonly myelosuppression, mucositis and alopecia [3] . Therefore, the major challenge in chemotherapy is to develop drug delivery systems (DDSs) to deliver chemotherapeutic drugs safely and efficaciously without side effects. Nano structured DDSs which are able to conjugate a drug have the capability to achieve targeted delivery of their content to cancer cells via the enhanced permeability and retention effects [4] . Current nano structured DDSs including nanoparticles, liposomes and micelles are mainly dispensed orally; through this route there are serious existing problems that still cannot be addressed adequately. Such as the lack of tissue specificity [5] , inefficient drug release at the tumour site and endosomal entrapment of nanocarriers, all of these significantly reduce efficacy [6] .
In order to overcome these barriers, implantable drug delivery (IDD) systems are still being developed. IDDSs originated in the 1960s when silicones were applied to prolong therapeutic efficiency [7] , this type of delivery was then recognized as a potential solution to address the issues associated with oral administration of specific therapies. However, little has been reported on the development of nano structured IDDSs, which could offer the potential of high drug loading and better cell uptake efficiency. Here, we supply an implantable, controllable drug-release nanofibrous M A N U S C R I P T
DDS, which can not only protect and deliver chemotherapeutic drugs to the specific site, but can also achieve controllable drug release therefore minimizing side effects.
Silkworm silks are a unique group of fibrous proteins with excellent mechanical strength in fibre form. The clinical use of silk sutures and availability of silkworm silk have encouraged a recent expansion of novel biomaterials from silkworms. Raw silks mainly consist of SF and silk sericin. The unique structure, versatility in processing, biocompatibility, various biomaterial morphologies, the ease of sterilization, thermal stability, surface chemistry for chemical modifications and water solubility features make SF a promising biomaterial for biomedical applications [8] [9] [10] [11] [12] . Recently, SF has elicited considerable interests in drug delivery, especially as implantable devices [1, 13] . However, little has been reported on SF-based nanofibrous matrix as IDDS for treatment of solid tumour cancers.
The natural polyphenolic compound curcumin (CM) is highly toxic on a wide range of cancers [14, 15] . Therefore, in this study CM was used as a drug model and 
Preparation of silk fibroin powder from raw silk fibres
The raw silk fibres of Bombyx mori were degummed three times to remove enveloped sericin in pressurized water at 120°C for 60 min. The degummed SF fibres were then immersed in a blend solution that contained calcium chloride, water, and ethanol with a molar ratio 1:8:2 for 6 h at 70°C until completely dissolved to obtain the regenerated SF solution. Thereafter, the regenerated SF solution was dialyzed against distilled water to remove the neutral salts by semi-permeable cellulose tubing (molecular weight cutoff 12,000-14,000) and to obtain the pure SF solution. Finally, dry SF powders were obtained by spray drying (outlet temperature ~110°C). The samples were kept at 4°C for further study.
Preparation of curcumin-silk fibroin nanofibrous matrix
First, CM and SF were mixed (1:19) , and then HFIP was added to the required concentration (6%). After complete dissolution, the blend solution was ready for SEDS (Fig. S1 ). When the desired pressure and temperature were reached, a steady flow of CO 2 (in and out of the vessel) was maintained to modulate the system pressure M A N U S C R I P T
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at a constant level. The blend solution was delivered into the high-pressure vessel simultaneously with the supercritical CO 2 flow. Enhanced mixing effect between the two flows was achieved using a specially designed nozzle. When the blend solution ran out, the fresh CO 2 flow was kept running for 2 h to completely remove the residual HFIP solvent. The CO 2 flow was then stopped, and the high-pressure vessel was slowly depressurized to atmospheric pressure. The material was collected on filters and vacuum dried at 60°C for 12 h and then kept at 4°C for further characterizations.
Solvent vapour post-treatment
After moulding into a round shape with radius 1.5 cm, the prepared CM-SF nanofibrous matrices were treated within atmospheres of water vapour, ethanol vapour and 25%, 50% and 75% ethanol vapour, separately, followed by drying in the hood overnight. Briefly, samples were put into sealed beakers saturated with water vapour, ethanol vapour and 25%, 50% and 75% ethanol vapour, and moved into the water bath for vapour treatment. The vapour treatment time ranged from 6-12 h, and the temperature was set at the range of 25-37 o C.
Surface morphology
The samples were directly adhered onto an aluminium stub with a thin self-adherent carbon film and then coated with a thin layer of gold. The surface morphology of the samples was observed via field emission scanning electron microscopy (SEM, JEOL, JSM-6490, Japan).
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Physicochemical characterizations
The samples were completely mixed with KBr and then pressed into a thin tablet.
The Fourier transform infrared spectroscopy (FTIR) spectra for the samples were obtained using FTIR Perkin Elmer 1720 (Perkin-Elmer, USA) in transmission mode with the wave number ranging from 4000 cm −1 to 400 cm −1 . The crystallinity of samples was evaluated using an X-ray diffractometer (D8 Advance, Bruker AXS, Germany) with Cu Kα (λ = 1.5405 Å) radiation. The measurement was performed in a 2θ range from 5° to 45° with a 0.02° step size and 10° min −1 scan speed with a 2D
detector at 40 kV and 40 mA.
In vitro drug release study
Drug release was determined using a modified dialysis bag method. Equal amounts of each sample were dispersed in 5 mL of phosphate buffer saline (PBS, pH 7.4) and placed in a pre-treated dialysis bag (molecular weight: 12,000-14,000
Daltons). The bag was then placed into 50 mL of PBS and incubated in a water bath at 37°C and 60 rpm. At specified time points, 1 mL of the solution was removed and centrifuged at 10,000 rpm for 10 minutes. The concentration of the supernatant was determined by UV spectrophotometer at wavelength 410 nm. The cumulative total amount released was calculated in terms of the CM concentration as a function of time.
Cell culture and proliferation
M
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HCT116 and NCM460 cells were maintained in Roswell Park Memorial Institute (RPMI) 1640 medium (Gibco, Invitrogen) supplemented with 10% FBS (Gibco, Invitrogen) and 1% pen-strep (100 U/ml penicillin and 100 µg/ml streptomycin) (Gibco, Invitrogen) in a 37 ± 0.2ºC humidified incubator containing 5% CO 2 , respectively. Further, cells were cultured as a monolayer culture and counted using a Cellometer Auto T4 (Nexcelom Bioscience LLC, USA).
Cellular uptake study
The 
MTS assay
Both anti-cancer effect of CM-SF nanofibrous matrices on colon cell line [16] . Tumour volume and mouse weight change ratio (%) were calculated using Eq. (3) and (4), respectively. The 5 groups were identified as: (1) and (2) Finally, the incision was sutured so that the tumour could be treated with the implanted CM-SF nanofibrous matrix directly.
Tumour volume change ratio % = V + V , ⁄ − 1 × 100%
Mouse weight change ratio % = W + W , ⁄ − 1 × 100%
Where: V is the volume of tumour, L is the tumour length, W is the tumour width, 
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H&E staining
All the tumours separated from the experimental mice were fixed in 10%
formalin solution, embedded in paraffin, sectioned at 5 µM, and stained with H&E for histopathological examination. Images of each tumour were captured at high magnification (×50 and ×200 fold) using the Leica DM IRB inverted research microscope (Leica Microsystems, Wetzlar, Germany).
Results and discussion
Surface morphology and chemical structure after ethanol vapour treatment
Scheme 1 shows the whole experimental design, to construct nano structured SF DDS, SEDS(supplementary Fig. S1 ). SEDS were modified following previously published protocols [17, 18] . The surface morphology and fibre diameter are very important factors that affect the physicochemical properties and biomedical functions [19] . Fig. 1 (a) shows that the CM-SF matrix had a nanofibrous structure with fibre diameter < 100 nm. Ethanol vapour treatment was employed to control drug release as shown in Fig. 1 . The temperature was set at 25-37 o C, and the treatment time was 6-12
h. The surface morphology of sample after ethanol vapour treatment was maintained ( Fig. 1, (b) );
The chemical structure and composition of CM-SF nanofibrous matrices after ethanol vapour treatment shown in Fig. 1, (c) . As can be seen, there were no significant changes in the amide II and amide III regions of SF after ethanol vapour M A N U S C R I P T
A C C E P T E D ACCEPTED MANUSCRIPT
treatments; however, the amide I region became more predominant with increased treatment time and temperature, which indicated that the silk I structure (α-helix and/or random coil conformation) became more stable (water-insoluble) when exposed to ethanol vapour with higher temperature and longer treatment time.
In vitro drug release after ethanol vapour treatment
However, the drug release profiles of CM-SF nanofibrous matrices after ethanol vapour treatments were different, that is, the release rate became slower with increased treatment time and temperature ( Fig. 1, (d) and (e)). The no treated group showed a higher release rate than the treated groups within 2 h, followed by a sharp decrease after two weeks. On the other hand, the ethanol vapour treated groups remained at a more stable release rate during the two-week experimental period, which suggested that ethanol vapour treated CM-SF nanofibrous matrices have long-term controllable drug release potential. The results are in agreement with previous studies on water-stable silk films with reduced β-sheet content [20] .
Controlled release of CM from SF-based nanofibrous matrices without inducing β-sheet transform could be explained by the formation of a stable silk I structure ( Fig.   1, (b) and (c)). Thus, CM-SF nanofibrous matrices treated by ethanol vapour could maintain their stable silk I structure (water-stable) and a long-term release rate without inducing β-sheet structural content.
Interactions of curcumin-silk nanofibrous matrix between cancer cells
To investigate the interaction between CM-SF nanofibrous matrices and cancer [20] , a more stale silk I structure in silk films favored initial cell-biomaterial interactions. Our observations were in agreement with a previous study on SF hydrogels, which suggested that the nanofibrous structure of SF-derived materials is important for cell attachment and cell-matrix interactions [21] .
Thus, we assumed that a more stable silk I structure of SF could ensure CM-SF maintained nanofibrous structure stable for a long time in water, allowing a stronger initial cell-biomatierial interactions. Another possible mechanism of the enhanced cell uptake efficiency are illustrated in Fig.2, (b) , that is, CM could be transported into cancer cells by endocytosis [22] . In a summary, we assumed that ethanol vapour M A N U S C R I P T
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treatment facilitated formation of stable silk I structure of SF, which could improve the transportation efficiency of CM into cancer cells by endocytosis.
In vitro anti-cancer efficiency of curcumin-silk fibroin nanofibrous matrix
In vitro anti-cancer effect (dose-depend) of CM-SF nanofibrous matrices was shown possessed a long-term stable anti-cancer effect that was mainly caused by continued delivery of CM to the cells.
Cytotoxicity of curcumin-silk fibroin nanofibrous matrix
The cytotoxicity of CM-SF nanofibrous matrices on normal cells (NCM460) at concentrations ranging from 2.5-40 µg/mL was shown in Fig. 3, (b) . It was found that 5-Fu had significant toxicity (~78%) from 2.5 µg/mL, and this toxic effect increased with increasing concentration. In contrast, both CM-DMSO and CM-SF nanofibrous matrix groups exhibited no toxicity at <5 µg/mL. However, a sharp increase in cytotoxicity was observed in the CM-DMSO group (~48%) at 10 µg/mL, but no cytotoxicity effect was found in the CM-SF nanofibrous matrix group until 40 µg/mL, suggesting that entrapment of CM in SF nanofibrous matrix could reduce the toxic effect within a smart treatment concentration range (STCR) (5-20 µg/mL) (Fig. 3, (e) ).
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STCR could be explained by the facts that (1) CM has a higher toxic effect on colon cancer cells than normal cells; (2) the entrapped CM is slowly released from the SF nanofibrous matrix with better control of CM concentration in the surrounding environment, which would result in higher uptake by cancer cells than normal cells due to difference in their metabolisms, thus reducing the adverse side-effects on normal cells. On the other hand, both the increased cell uptake ability (Fig. 2) and enhanced permeability and retention (EPR) effect of CM-SF nanofibrous matrix contribute to the enhanced anti-cancer effect. The pure SF control group displayed no toxicity through the test concentration range.
Evaluations of the time-dependent cytotoxicity on normal cells (NCM460) were also performed to study the long-term in vitro toxic effect of CM-SF nanofibrous matrices with or without ethanol vapour post-treatment (Fig. 3, (d) ). As can be seen, 5-Fu at IC50 exhibited a toxic effect from day 0-6. On the other hand, the pure SF control and CM-SF nanofibrous matrices with or without post-treatment exhibited no toxic effect within the whole experimental period. In conclusion, incorporating CM into SF nanofibrous matrix after ethanol vapour treatment could have a smart treatment potential in cancer therapy.
Cell cycle arrest by curcumin-silk fibroin nanofibrous matrix
To further investigate the mechanism for the observed inhibition of colon cancer cells by CM-SF nanofibrous matrices, We studied the cell cycle of HCT116 cells treated with different groups at IC50 concentration for 24 and 48 h (Fig. 4, (a) and (c) ). 
Induction of cell apoptosis by curcumin-silk fibroin nanofibrous matrix
Previous research has reported that CM is responsible for inducing apoptosis in a variety of cancers including breast, lung, pancreatic and colon [24] [25] [26] . To study the potential of CM-SF nanofibrous matrices to induce apoptosis in colon cancer cells In summary, the results demonstrated that CM-SF nanofibrous matrices after ethanol vapour treatment have higher apoptotic cell induction which was responsible for the higher anti-cancer effect. Our results were similar to a previous study on CM-loaded polymeric micelles for the treatment of colon cancers [27] , which suggested that the mechanism of inhibition of growth of colon cells was due to increased apoptosis associated with cell cycle arrest. The mechanism of cell apoptosis induction of CM could be through the inhibition of key anti-apoptotic proteins, Mcl-1, Bcl-xL which cause the induction of PARP cleavage [28] .
In vivo solid tumour treatment
Implantation of CM-SF nanofibrous matrices for the treatment of solid tumours in vivo was performed, 
H&E stain analysis
To study the anti-cancer mechanism, histological analysis of tumour sections was performed at the 12 th day. All the tumours obtained from the experimental mice were H&E stained and observed under the optical microscope. The representative areas were captured (above: ×50; beneath: ×200). As shown in ratios. This result corresponded to the previous in vitro cell apoptosis analysis (Fig. 4) .
As a result of direct contact with tumour tissue, CM-SF nanofibrous matrices presented the slowest growth of tumours. The tumour volume and tumour weight were smaller and lower than other groups, fewer necrotic but more apoptotic cells were observed. In a summary, this result suggested that implantation of CM-SF nanofibrous matrix provided superior induction of apoptosis in vivo.
Conclusions
In conclusion, CM-SF nanofibrous matrices had improved intracellular uptake, this resulted in an enhanced anti-cancer effect. The mechanism could be explained by cell cycle arrest in the S phase in association with inducing apoptosis in tumour cells. 
